November 12, 2012 15:08
FAS green-lights AFK Sistema bid to buy 100% of VeroPharm, but with terms (Part 2)
MOSCOW. Nov 12 (Interfax) - Russia's Federal Antimonopoly Service (FAS) has approved AFK Sistema's (RTS: AFKS) request for permission to buy 100% of the stock in pharmaceuticals company OJSC VeroPharm (RTS: VRPH), but has attached some terms, a FAS statement says.
The FAS established that VeroPharm has a dominating position on the market for medicines with MNN Gemifloksatsin, and its subsidiary LLC LENS-Pharm with MNN Poliadenilovaya Kislota + Poliuridilovaya Kislota.
The FAS takes the view that the conduct of this deal could lead to a limiting of access to the market for the sale of these medical preparations by independent counteragent VeroPharm and LENS-Pharm. In light of this, the FAS requires of Sistema and VeroPharm to ensure the fulfillment of all contracts for the delivery of all medicines existing on the date the deal is completed.
Before the deal is done, Sistema is to post on its official website the document regulating its commercial policy as regards VeroPharm medical preparations, and announce changes to commercial policy in letter form to the FAS within thirty days.
The parties are not to, from the date the deal is completed, effect any unfounded economic or technological reduction or halt of the production and supply of goods that are still in demand. They are also to announce to the FAS either of such circumstances in letter form within thirty days.
AFK Sistema and VeroPharm are to annually inform the FAS in letter form that they are meeting these conditions.
The parties to the deal are to announce its completion to the anti-monopoly agency within twenty days from the day the deal is wrapped up.
According to DSM Group data, VeroPharm is third in a rating of the largest Russian pharmaceutical companies. Company product is provided by three plants: in Belgorod, Voronezh, and Pokrov. VeroPharm specializes in the production of Rx medical goods, which account for about 70% of its sales revenues.
Pharmacy Chain 36.6 (RTS: APTK) owns 51.8% of the company.
(Our editorial staff can be reached at email@example.com)
April 27, 2017
Moscow to work with whoever comes to power in Iran elections, hopes to maintain positive dynamics in relations - Foreign Ministry
New chairman of Kazakhstan's KAZ Minerals Board of Directors named
GAZPROM AGREEM ENTS WITH EC ANTIMONOPOLY BODY MAY EVEN LEAD TO HIGHER REVENUE AND WILL FACILITATE IMPLEMENTATION OF PROJECTS - GAZPROM DEPUTY CEO
NLMK DIVIDENDS FOR Q1 MAY BE HIGHER THAN DIVIDEND POLICY LEVEL - COMPANY
Moscow concerned about Turkey's actions toward Kurds in Iraq, Syria - Foreign Ministry (Part 2)
Russian ship Liman that sank in Black Sea observed navigation rules - source
Gazprom aiming to maintain ruble equivalent value of 2017 dividends in 2018-2019
Loss of Black Sea Fleet's Liman is unprecedented event - Adm. Kravchenko
Defendants in Sugrobov case sentenced to terms ranging from 4 to 22 years in jail
Gazprom department head: 2017 investment to be at 2016 level - 1.7 trln rubles or a little more
Peresvet bank reduces charter capital to 1 ruble
GAZPROM EXPECTS INVESTMENT IN 2017 AT 2016 LEVEL - 1.7 TRLN RUBLES, PERHAPS A LITTLE MORE - DEPARTMENT DIRECTOR
Russia plans to fly prospective long-range aircraft in 2025-2026 - Russian deputy defense minister